The DOI matches its Crossref record.
Intravesical Evans Strain BCG Therapy: Quantitative Immunohistochemical Analysis of the Immune Response within the Bladder Wall
Abstract
Previous studies have demonstrated that is is the local immune response which is of importance for the anti-tumour activity of BCG therapy. We have investigated this by quantitative immunohistochemical analysis of serial bladder mucosal biopsies taken before, during and after an eight week course of intravesical Evans strain BCG therapy and three monthly thereafter in 16 patients (15 extensive CIS and one extensive G2pTa papillary tumour). This particular group of patients had a 67% complete response rate at six months post-treatment. The main findings on immunohistochemical analysis were the universal induction of MHC Class II antigens by urothelial cells which was statistically significant up to 6 months after completion of therapy, coupled with a T cell dominated cystitis. Increases in CD3+ T cell infiltration of the lamina propria and that of the CD4+ "Helper" subset which predominated were significant up to 3 months post-therapy and these cells showed evidence of increased immunological activation as shown by increased interleukin-2 receptor and MHC Class II antigen expression. There were also significant increases in CD68+ macrophage and the incidence of CD22+ B cell aggregates but CD57+ NK cells were sparse both before and after therapy. The degree of mononuclear cell infiltration for all markers examined (except CD57) was significantly greater in those biopsies in which the urothelial cells expressed MHC Class II antigens than in those that did not. Also the degree of T cell infiltration (CD3, CD4 and CD8) was significantly greater in the eight patients deemed to have had a complete response compared to those seven with a partial response or treatment failure. These results are discussed in terms of possible mechanisms of action for BCG therapy and in particular the role of enhanced antigen presentation by tumour cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The mechanism of action of BCG therapy for bladder cancer--a current perspective
Redelman-Sidi, G., Glickman, M. S., & Bochner, B. H. (2014) · Nature Reviews Urology · doi:10.1038/nrurol.2014.15 · Cited by 729
BCG immunotherapy of bladder cancer: 20 years on
Alexandroff, A. B., Jackson, A. M., O'Donnell, M. A., & James, K. (1999) · The Lancet · doi:10.1016/s0140-6736(98)07422-4 · Cited by 471
Self-citationBCG-Induced Cross-Protection and Development of Trained Immunity: Implication for Vaccine Design
Covián, C., Fernández-Fierro, A., Retamal-Díaz, A., Díaz, F. E., Vasquez, A. E., Lay, M. K., Riedel, C. A., González, P. A., Bueno, S. M., & Kalergis, A. M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02806 · Cited by 328
Immune Mechanisms in Bacillus Calmette-Guerin Immunotherapy for Superficial Bladder Cancer
BÖHLE, A., & BRANDAU, S. (2003) · Journal of Urology · doi:10.1097/01.ju.0000073852.24341.4a · Cited by 318
Preexisting BCG-Specific T Cells Improve Intravesical Immunotherapy for Bladder Cancer
Biot, C., Rentsch, C. A., Gsponer, J. R., Birkhäuser, F. D., Jusforgues-Saklani, H., Lemaître, F., Auriau, C., Bachmann, A., Bousso, P., Demangel, C., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003586 · Cited by 269
Metadata
- Authors
- Prescott, S., James, K., Hargreave, T. B., Chisholm, G. D., & Smyth, J. F.
- Venue
- Journal of Urology
- Published
- 1992-06
- Volume
- 147
- Issue
- 6
- Pages
- 1636-1642
- ISSN
- 0022-5347 (ISSN-L)
- 1527-3792
- OpenAlex
- W1709508
- Cited by
- 214
- References
- 0
- FWCI
- 7.84
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Intravesical Evans Strain BCG Therapy: Quantitative Immunohistochemical Analysis of the Immune Response within the Bladder Wall. https://app.cochat.ai/papers/10.1016/s0022-5347(17)37668-1
- The paper
- Prescott, S., James, K., Hargreave, T. B., Chisholm, G. D., & Smyth, J. F. (1992). Intravesical Evans Strain BCG Therapy: Quantitative Immunohistochemical Analysis of the Immune Response within the Bladder Wall. Journal of Urology. https://doi.org/10.1016/s0022-5347(17)37668-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.